Skip to main content
$3.60 -$0.02 (-0.6%)

04:00 PM EDT on 05/14/21

Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

CAPS Rating: 5 out of 5

Current Price $3.60 Mkt Cap $354.5M
Open $3.64 P/E Ratio 0.00
Prev. Close $3.62 Div. (Yield) $0.00 (0.0%)
Daily Range $3.58 - $3.73 Volume 2,353,455
52-Wk Range $3.46 - $26.98 Avg. Daily Vol. 2,980,076


How do you think NASDAQ:ADVM will perform against the market?

Add Stock to CAPS Watchlist

All Players

37 Outperform
1 Underperform

All-Star Players

7 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:ADVM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Bigsef77 (71.09)
Submitted September 21, 2018

Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMDGlobeNewswire•September 19, 2018ADVM-022 is a unique single-administration gene therapy delivered intravitreally for the treatment of wAMDOPTIC… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


Fools bullish on NASDAQ:ADVM are also bullish on:

Fools bearish on NASDAQ:ADVM are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ADVM.


Member Avatar TerryHogan (99.36) Submitted: 2/6/2021 12:26:25 AM : Outperform Start Price: $13.83 NASDAQ:ADVM Score: -80.98

High technical trading algorithm says it's a buy. Algo is this: MKTCAP < $1B AND NAME = *Biotech* THEN buy 100 shares


Member Avatar Bigsef77 (71.09) Submitted: 9/21/2018 4:29:03 PM : Outperform Start Price: $3.25 NASDAQ:ADVM Score: -44.39

Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD
GlobeNewswire•September 19, 2018
ADVM-022 is a unique single-administration gene therapy delivered intravitreally for the treatment of wAMD
OPTIC Phase 1 clinical trial initiation expected in 4Q18
MENLO PARK, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ADVM-022. ADVM-022 is a novel gene therapy candidate for the treatment of wet age-related macular degeneration (wAMD).

“The FDA’s Fast Track designation is an important recognition of our ADVM-022 gene therapy program,” said Leone Patterson, interim president and chief executive officer of Adverum Biotechnologies. “We look forward to working with the FDA and benefiting from the potential expedited development and regulatory path offered by their Fast Track program.”

A Fast Track designation is intended to facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill unmet medical needs. The designation enables more frequent communication with the FDA throughout a product candidate’s development and review process. The designation also provides eligibility for Priority Review and Accelerated Approval, which may potentially result in a shorter FDA review process.


Member Avatar jclaypool (< 20) Submitted: 8/30/2018 6:09:33 AM : Outperform Start Price: $6.50 NASDAQ:ADVM Score: -87.80

New products are going into clinical trials.


Find the members with the highest scoring picks in ADVM.

Score Leader


PAGEBOY73 (98.77) Score: +187.22

The Score Leader is the player with the highest score across all their picks in ADVM.

Member Name Member
Call Time
Score Commentary
zzlangerhans 98.86 11/9/2018 Underperform 1Y $3.74 -3.74% +50.06% +53.81 0 Comment
Proudfoot 42.40 1/25/2019 Outperform 5Y $3.15 +14.29% +56.62% -42.33 0 Comment
Bigsef77 71.09 12/19/2017 11/14/2018 Outperform 3Y $3.25 +10.77% +55.16% -44.39 2 Comments
Under5 69.16 2/8/2019 Outperform 5Y $3.34 +7.78% +55.01% -47.22 0 Comment
Momentum21 43.57 12/8/2017 Outperform 5Y $3.30 +9.09% +57.21% -48.12 0 Comment
q10 < 20 12/20/2017 Outperform 5Y $3.35 +7.46% +55.89% -48.43 1 Comment
stainsolution 66.38 1/2/2018 Outperform 5Y $3.65 -1.37% +55.53% -56.90 0 Comment
Haugurafpeningum 32.47 9/30/2019 Outperform 5Y $5.25 -31.43% +40.75% -72.18 0 Comment
axnxg 75.71 1/8/2021 Outperform 5Y $12.16 -70.39% +9.46% -79.85 0 Comment
TerryHogan 99.36 2/8/2021 Outperform 5Y $13.83 -73.96% +7.02% -80.98 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ADVM.